Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
Other Sizes |
|
ln Vitro |
Incubating tumor cells with 10 mM L-2,4-diaminobutyric acid for 24 hours at 37°C causes irreversible and total destruction. L-DABA's cell-damaging actions could be attributed to osmotic lysis caused by non-saturated intracellular buildup of the compound. L-DABA's deleterious effects can be removed by incubating it with L-alanine and L-methionine at the same time [1]. Kinetic investigations show that L-DABA is a non-linear, non-competitive inhibitor of GABA transaminase activity. The rise in GABA levels induced by L-DABA is consistent with the suppression of GABA transaminase activity [2]. L-2,4-diaminobutyric acid is an amino acid analog that has cytotoxic effects on the human glioma cell line SKMG-1 and normal human fibroblasts. The L-DABA concentration needed to reduce cell counts to 50% of control after 24 hours of incubation at 37°C is 12.5 mM for human fibroblasts and 20 mM for glioma cell lines [3].
|
---|---|
ln Vivo |
Treatment with L-DABA can stop tumor growth by 43.4%[1]. In vivo, L-DABA inhibits GABA transaminase more potently than it does in vitro [2].
|
References |
[1]. Ronquist G, et al. Antitumor activity of L-2,4 diaminobuturic acid against mouse fibrosarcoma cells in vitro and in vivo. J Cancer Res Clin Oncol. 1980;96(3):259-68.
[2]. Beart PM, et al. l-2,4-Diaminobutyric acid and the GABA system. Neurosci Lett. 1977 Jul;5(3-4):193-8. [3]. Panasci L, et al. The cytolytic effect of L-2,4 diaminobutyric acid with malignant glioma cells and fibroblasts. Cancer Chemother Pharmacol. 1988;21(2):143-4 |
Molecular Formula |
C4H10N2O2.HBR
|
---|---|
Molecular Weight |
199.04634
|
CAS # |
1758-80-1
|
Related CAS # |
(S)-L-DABA dihydrochloride;1883-09-6
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C(O)[C@@H](N)CCN
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~1 mg/mL (~8.47 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (846.53 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 5.0239 mL | 25.1193 mL | 50.2386 mL | |
5 mM | 1.0048 mL | 5.0239 mL | 10.0477 mL | |
10 mM | 0.5024 mL | 2.5119 mL | 5.0239 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.